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Abstract 
Background: PRL-3 is a phosphatase implicated in oncogenesis in multiple cancers. In some cancers, notably car-
cinomas, PRL-3 is also associated with inferior prognosis and increased metastatic potential. In this study we investi-
gated the expression of PRL-3 mRNA in fresh-frozen samples from patients undergoing radical prostatectomy because 
of prostate cancer (PC) and the biological function of PRL-3 in prostate cancer cells.
Methods: Samples from 41 radical prostatectomy specimens (168 samples in total) divided into low (Gleason 
score ≤ 6), intermediate (Gleason score = 7) and high (Gleason score ≥ 8) risk were analyzed with gene expression 
profiling and compared to normal prostate tissue. PRL-3 was identified as a gene with differential expression between 
healthy and cancerous tissue in these analyses. We used the prostate cancer cell lines PC3 and DU145 and a small 
molecular inhibitor of PRL-3 to investigate whether PRL-3 had a functional role in cancer. Relative ATP-measurement 
and thymidine incorporation were used to assess the effect of PRL-3 on growth of the cancer cells. We performed an 
in vitro scratch assay to investigate the involvement of PRL-3 in migration. Immunohistochemistry was used to iden-
tify PRL-3 protein in prostate cancer primary tumor and corresponding lymph node metastases.
Results: Compared to normal prostate tissue, the prostate cancer tissue expressed a significantly higher level of 
PRL-3. We found PRL-3 to be present in both PC3 and DU145, and that inhibition of PRL-3 led to growth arrest and 
apoptosis in these two cell lines. Inhibition of PRL-3 led to reduced migration of the PC3 cells. Immunohistochemistry 
showed PRL-3 expression in both primary tumor and corresponding lymph node metastases.
Conclusions: PRL-3 mRNA was expressed to a greater extent in prostate cancer tissue compared to normal prostate 
tissue. PRL-3 protein was expressed in both prostate cancer primary tumor and corresponding lymph node metas-
tases. The results from our in vitro assays suggest that PRL-3 promotes growth and migration in prostate cancer. In 
conclusion, these results imply that PRL-3 has a role in the pathogenesis of prostate cancer.
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Background
Phosphatase of regenerating liver (PRL)-3 (gene name 
PTP4A3) is a dual-specificity phosphatase, and thus able 
to dephosphorylate both tyrosine and serine/threonine 
residues. Increased interest in the PRL family was trig-
gered in 2001, when Saha et al. [1] conducted a study on 
colorectal cancer, and found PRL-3 to be overexpressed 
in liver metastases, but not in the primary tumor nor the 
normal colon tissue. In recent years, additional studies 
have investigated PRL-3 in different cancers and found 




*Correspondence:  estennv@stud.ntnu.no 
1 K. G. Jebsen Center for Myeloma Research, Norwegian University 
of Science and Technology, PO Box 8905, 7491 Trondheim, Norway
Full list of author information is available at the end of the article
Page 2 of 11Vandsemb et al. J Transl Med  (2016) 14:71 
metastatic potential and poor prognosis. Similar results 
have been found in a wide variety of cancers, including 
colorectal cancer [2–4], breast cancer [5], cervical cancer 
[6], gastric cancer [7–9], ovarian cancer [10], lung cancer 
[11] and AML [12].
The morbidity and mortality of cancer is closely related 
to the spread of metastases. In this process, the tumor 
cells go through several cellular transformations to be 
able to colonize distant sites. A key feature of the trans-
formation is the ability to migrate. This ability is acquired 
as the cell undergoes an epithelial-mesenchymal transi-
tion (EMT), which is essential for metastatic dissemina-
tion. Several studies have shown a connection between 
PRL-3 and EMT [13–16], indicating that PRL-3 could 
have a role in EMT. The process of metastasis is not fully 
understood, and the definitive role of PRL-3 remains 
obscure.
Prostate cancer (PC) is the second most common can-
cer among males worldwide, and the most common can-
cer among males in developed countries [17]. It is a very 
heterogeneous disease, spanning from indolent cancer 
with excellent survival, to a highly aggressive disease with 
rapid metastatic spread to lymphatic glands and bone. 
An integrated analysis of copy number alterations and 
expression, in combination with data from online data-
bases (e.g. Oncomine), identified PRL-3 as a possible fac-
tor for tumor progression [18]. The evidence supporting 
the involvement of PRL-3 in cancer metastasis is growing 
rapidly, but when it comes to PRL-3 and mechanisms in 
prostate cancer, the literature is limited. Here we present 
data elucidating some of the mechanisms PRL-3 could 
be involved in, and thus contribute to oncogenesis in 
prostate cancer. A better understanding of the molecular 
mechanisms of prostate cancer metastasis is of utmost 
importance for the development of improved therapeu-
tic strategies and better risk stratification of patients 
with this malignancy. In this study, we hypothesized 
that PRL-3 is present in prostate cancer and that it has a 
functional role in disease progression. Hence, we studied 
whether PRL-3 mRNA and protein were present in fresh-
frozen prostate samples from patients operated with 
radical prostatectomy, and whether it had an effect on 
proliferation and migration in prostate cancer cell lines.
Methods
Cells and reagents
We used the human prostate cancer cell lines PC3 and 
DU145 (from ATCC). DU145 was grown in Dulbecco’s 
Modified Eagle Medium (DMEM), and PC3 in Roswell 
Park Memorial Institute medium-1640 (RPMI), sup-
plemented with 2  mmol/L l-glutamine, 40  µg/mL gen-
tamicin and 10 % heat-inactivated fetal calf serum (FCS). 
The cell lines were cultured at 37  °C in a humidified 
atmosphere with 5  % CO2. Trypsin was used prior to 
experiments and culturing for 8–10  min to detach the 
adherent cells from the plastic flasks and plates. The cells 
were subcultured twice a week. Cells were washed with 
Hanks’ balanced salt solution (HBSS) (Sigma-Aldrich, St. 
Louis, MO, USA). PRL-3 inhibitor I (5-[[5-Bromo-2-[(2-
bromophenyl)methoxy]phenyl]methylene]-2-thioxo-
4-thiazolidinone) was from Sigma-Aldrich (St. Louis, 
MO, USA). Dimethyl sulfoxide (DMSO) controls were 
included since the inhibitor was dissolved in DMSO. The 
antibodies against PRL-3 (ab50276) and GAPDH were 
both from Abcam (Cambridge, UK).
Gene expression profiling
A total of 156 samples were extracted from 41 fresh-
frozen slices from patients undergoing radical prosta-
tectomy at the St. Olavs Hospital–Trondheim University 
Hospital. Patients planned for radical prostatectomy 
were invited to donate tissue and sign an informed con-
sent form prior to surgery. The Regional Committee for 
Medical Research Ethics in Central Norway (REC Cen-
tral) approved the collection of samples. The samples 
were stained with hematoxylin and eosin and scored 
according to the Gleason Grading system by a patholo-
gist trained in uropathology, and divided into normal 
(n = 40), low grade (Gleason score = 6, n = 38), inter-
mediate grade (Gleason score  =  7, n  =  42) and high 
grade (Gleason score ≥  8, n =  36). Cancerous samples 
were selected from index tumor, and the samples with 
benign histology were taken as far from index tumor 
as possible. RNA was extracted manually with mirVana 
miRNA Isolation Kit (Ambion Inc.). Illumina Total-
Prep RNA amplification Kit (Ambion Inc.) was used for 
amplification of RNA for hybridization. Total RNA from 
each sample was used to synthesize first-strand cDNA 
with reverse transcription. After synthesis of second-
strand cDNA and purification, cRNA was synthesized 
via in  vitro transcription for 12  h. Illumina Human 
HT-12 v4 Expression BeadChip (Illumina) was used to 
measure gene expression. The Minimum Information 
about a Microarray Gene Experiment (MIAME) guide-
lines were followed, and the microarray data prepared 
in a fitting format. Individual cancer and stroma con-
tributions to gene expression was assessed by creating 
two sample groups where the average stroma content are 
maximized and minimized between cancer and normal 
samples (Rye et al., submitted and Additional file 1). The 
same strategy was also applied to an independent data-
set [19] for validation. Our data can be found in array 
express with accession number: E-MTAB-1041. Method 
used for fresh tissue harvesting, sample extraction and 
gene expression analysis is more thoroughly explained 
by Bertilsson et al. [20, 21].
Page 3 of 11Vandsemb et al. J Transl Med  (2016) 14:71 
Measurement of PRL‑3 mRNA with real‑time PCR
Non-stimulated cells were washed 4× with HBSS prior 
to RNA isolation. The RNeasy Mini Kit (Qiagen, Craw-
ley, UK) was used to isolate total RNA from PC3 and 
DU145 cell lines. Synthesis of cDNA was done by 
reverse-transcription of 1.0 µg total RNA, using the High 
Capacity RNA-to-cDNA kit (Life Technologies, Carls-
bad, CA, USA), by applying oligo (dT) primers. PTP4A3 
(Hs00754750_m1) TaqMan® primer was used to detect 
gene expression (Life Technologies, Carlsbad, CA, USA). 
The ΔΔCT-method was used for quantification using 
GAPDH (Hs99999905_m1) as endogenous reference.
Immunoblotting
Cells were treated as indicated, collected, pelleted and 
resuspended in lysis buffer: 1 % NP40, 150 mmol/L NaCl, 
50  mmol/L TrisHCl pH 7.5, 10  % glycerol, 1  mmol/L 
NaF, 2  mmol/L Na3VO4 and a protease-phosphatase 
inhibitor mixture (complete mini tablets, Roche, Basel, 
Switzerland). After 30  min on ice, the nuclei were pel-
leted by centrifugation at 12,000×g, 4  °C for 20  min. 
Samples were mixed with lithium dodecyl sulfate sam-
ple buffer (Invitrogen) with 10  mmol/L dithiothreitol, 
heated for 10 min at 70  °C and separated on 10 % Bis–
tris gels (Invitrogen). Proteins were then transferred to 
a nitrocellulose membrane with iBlot® dry blotting sys-
tem (Invitrogen). After blocking the membranes with 5 % 
BSA in TRIS-buffered saline containing 0.05 % Tween 20 
(TBS-T), the membranes were incubated with antibod-
ies against phosphorylated proteins for 1–3 days at 4 °C. 
Horseradish peroxidase-conjugated antibodies (DAKO 
Cytomation, Copenhagen, Denmark) and Supersignal® 
West Femto Maxiumum Sensitivity Substrate (Thermo 
scientific, Rockford, IL, USA) were used to detect pro-
tein signal. The membranes were stripped at 60  °C for 
30 min with gentle rotation in stripping buffer containing 
62.5 mmol/L Tris–HCl (pH 6.6), 2 % SDS, and 10 mmol/L 
2-mercaptoethanol, then washed in Tris-buffered saline 
with 0.05 % Tween 20, blocked with 5 percent dry milk 
in TBS-T, and probed with antibodies against GAPDH. 
Images were taken with LI-COR Odyssey Fc (LI-COR 
Biosciences, Lincoln, NE, USA).
Relative ATP‑measurement
The relative rate of cell proliferation was estimated 
by measuring the content of ATP present in the wells 
using CellTiter-Glo Luminescent (CTG) Cell Viability 
Assay (Promega, Madison, WI, USA). We followed the 
instructions provided by the manufacturer. In short, PC3 
(20,000) and DU145 (15,000) cells were seeded in quin-
tuples in a 96-well plate and incubated in RPMI/DMEM 
containing 10  % FCS, with various concentrations of 
PRL-3 inhibitor I or DMSO for 72 h at 37 °C in a 5 % CO2 
atmosphere. The provided assay reagent was then added 
to the plates, after which the plates were agitated on a 
microplate shaker for 2 min, and kept at room tempera-
ture for 10 min before we determined the luminescence. 
The luminescent signal was recorded with Victor3 plate 
reader and Wallac 1420 Work Station software (Perki-
nElmer Inc., Waltham, MA, USA).
Thymidine incorporation
The prostate cancer cell lines PC3 and DU145 were 
washed in HBSS four times before seeded into 96-well 
culture plates with 10 % FCS in RPMI or DMEM, respec-
tively. Next, the cells were treated with various concen-
trations of the PRL-3 inhibitor I or DMSO. After 56  h, 
cells were pulsed with 1  µCi of methyl-[3H]-thymidine 
(NEN Life Science Products, Boston, MA, USA) per well 
and harvested 16 h later with a Micromate 96-well har-
vester (Packard, Meriden, CT, USA). The radiation was 
then measured with a Matrix 96 β counter (Packard).
Flow cytometry
Viability and apoptosis were investigated by evaluat-
ing annexin V-FITC binding and propidium iodide (PI) 
uptake (APOPTEST-FITC kit; Nexis Research, Kat-
tendikje, The Netherlands) with flow cytometry. The cells 
were trypsinized before being respuspended, washed 
4 times in HBSS, and seeded in 24-well culture plates 
in 1  mL medium with either RPMI or DMEM (PC3 or 
DU145, respectively) containing 10  % FCS. Cells were 
then treated with various concentrations of PRL-3 inhibi-
tor I as indicated. After 72  h, the cells were harvested 
and washed in PBS. After washing, the cells were resus-
pended in 300 μL binding buffer, added 0.25 μL annexin 
V-fluorescin isothiocyanate (FITC), and incubated on 
ice for 1  h in the dark. Next, PI was added 5  min prior 
to analysis. BD LSRII Flow Cytometer (BD Biosciences, 
Franklin Lakes, NJ, USA) was used to classify cells as 
annexin V-FITC and/or PI-negative or -positive. Cells 
negative for both PI and annexin V were considered live 
cells.
Fluorescence in situ hybridization (FISH)
FISH was done according to standard procedure using 
metaphases [22]. The PRL-3 probe was prepared from 
BAC clone RPCI-11953B20 containing the whole PRL-
3 gene (Invitrogen) and labeled with SpectrumOrange 
dUTP using nick translation (Vysis). Whole chromo-
some paint for chromosome 8 in green (Applied Spec-
tral Imaging, Micro System AB, Spånga, Sweden) was 
used to determine if the gene was translocated to another 
chromosome.
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In‑vitro scratch assay
10 × 105 PC3 cells were seeded in 1.5 mL media in each 
well into a 6-well plate. The cells were grown to a con-
fluent layer (48 h), and then a scratch was made in each 
well by using a pipette tip. Subsequently, the cells were 
washed gently with PBS, and then various concentrations 
of PRL-3 inhibitor I in serum-free media were added to 
the wells. Start picture was taken at time point 0. The 
cells were then incubated at 37  °C in a 5 % CO2 atmos-
phere, and new pictures were taken after 16 h. The 16 h 
time point was chosen to decrease the potential impact 
of proliferation on the closing of the scratch. ImageJ from 
NIH was used to standardize and present the results.
Immunohistochemistry (IHC)
Samples (4  µm sections) from paraffin-embedded tis-
sue blocks were pretreated in target retrieval solution 
(pH  =  9), Dako (K8004) in PT Link (Dako, Oslo, Nor-
way) for 20 min at 97 °C. Subsequently, the samples were 
incubated with antibody from Abcam (ab50276) against 
PRL-3 (diluted 1:300) for 40  min in room temperature. 
The detection system used was EnVision/HRP Rabbit, 
Dako (K4011).
Results
Tissue microarray data showed a significant difference 
between normal and cancerous samples in regards to the 
expression of PRL‑3
A total of 156 samples from 41 different patients were 
examined, 40 of the samples were classified as having a 
normal histology. Of the 116 cancer samples, 38 were 
classified as low risk cancer (Gleason score ≤ 6), 42 sam-
ples showed intermediate risk (Gleason score =  7) and 
36 samples were classified as high risk cancer (Glea-
son score  ≥  8). When investigating these samples for 
expression of PRL-3, four different probes were used. 
As shown in Fig.  1, we found a significant difference in 
PRL-3 expression between normal samples and samples 
containing cancerous tissue. We did not see any signifi-
cant difference between the groups with different Glea-
son-score. P values for the different groups compared to 
normal are given in the supplementary file. In addition, 
expression differences in PRL-3 improved for all four 
probes when effects of confounding stroma in the tis-
sue samples were separated from differences related to 
cancer (see Additional file  1). The same trend was also 
observed for both probes in an independent dataset. Both 
datasets ranked PRL-3 among the top 125 cancer related 
genes after adjusting for stroma effects. Taken together, 
the results of these tissue microarray studies suggest that 
PRL-3 plays a significant role in the pathogenesis of pros-
tate cancer.
PRL‑3 was expressed in prostate cancer cell lines PC3 
and DU145 and the cell lines harbored multiple copies 
of the PRL‑3 gene locus
To establish the presence of PRL-3 in our prostate can-
cer cell lines we used quantitative real-time PCR. The 
results showed that PRL-3 was expressed at detectable 
mRNA-levels in both of the prostate cancer cell lines PC3 
and DU145 (Fig. 2a). Western blots confirmed PRL-3 to 
be present in both cell lines (Fig. 2b). As a positive con-
trol we used the multiple myeloma cell line INA-6, which 
has a high endogenous levels of PRL-3 protein. In a sub-
sequent FISH analysis, we examined whether the high 
expression of PRL-3 could be a result of gene amplifica-
tion. PC3 cell line had two normal copies of chromosome 
8 and four parts of chromosome arm 8q that had been 
translocated to other chromosome, resulting in six cop-
ies of PRL-3 gene in total (Fig. 2c). DU145 cell line had 
three copies of chromosome 8 and thus three copies of 
the PRL-3 gene (Fig. 2d).
Inhibition of PRL‑3 led to growth arrest of the prostate 
cancer cell lines PC3 and DU145
We next examined whether PRL-3 was important for 
proliferation and protection from apoptosis in the pros-
tate cancer cells. The effect of an inhibitor of PRL-3 was 
evaluated by relative ATP-measurement and 3H-thymi-
dine incorporation. The inhibitor induced growth arrest 
in a dose-dependent manner in both PC3 (Fig.  3a +  c) 
and DU145 (Fig. 3b + d) with an IC50 value of 9.9 µM 
(PC3, Fig.  3a) and 10.4  µM (DU145, Fig.  3b). We stud-
ied the effect of PRL-3 inhibitor on apoptosis using flow 
cytometry. At high concentrations (40  µM) of PRL-3 
inhibitor influenced survival in the two cell lines tested 
(Fig. 3e, f ). The PRL-3 inhibitor did not affect the survival 
of normal bone marrow stromal cells (BMSCs) at the 
concentrations used in this paper (data not shown) indi-
cating that there was no off-target effect of the inhibitor 
at doses applied. Taken together, these results suggests 
that PRL-3 might be important for prostate cancer cell 
proliferation and possibly protection against apoptosis.
Inhibition of PRL‑3 decreased the migration of PC3 
prostate cancer cells
We further evaluated the effect of PRL-3 inhibitor I on 
migration in an in vitro scratch assay. As shown in Fig. 4 
there was a reduction in the migratory ability of the PC3 
prostate cancer cells when we inhibited PRL-3, and the 
inhibition of migration seemed to increase with increas-
ing concentrations of the inhibitor. The lowest concentra-
tion of PRL-inhibitor I sufficient to provide a visual effect 
on the migratory ability of the cells was between 5 and 
10 µM.
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PRL‑3 was highly expressed in prostate cancer tumor 
samples and corresponding metastases
To evaluate whether PRL-3 was expressed on protein 
level in prostate cancer, we performed immunohisto-
chemistry on four patient samples and corresponding 
lymph node metastases. All primary tumors expressed 
PRL-3 in morphologically malignant parts of the samples 
(Fig.  5a), but some normal glands also stained positive 
(Fig. 5a, Patient 4). The corresponding metastases stained 
positive for PRL-3 (Fig. 5b).
Discussion
To our knowledge, this is the first article demonstrat-
ing a pathogenetic role for PRL-3 in prostate cancer. We 
found a significant difference in mRNA level between 
normal samples and samples with malign phenotype. 
We investigated the functional importance of this find-
ing with several in vitro assays. Our results indicated that 
PRL-3 could have a role in the proliferation and migra-
tion of prostate cancer cells, and thus could contrib-
ute to carcinogenesis and the formation of metastases. 
Research done in the last decade shows that PRL-3 is 
overexpressed in carcinomas and predicts poor progno-
sis [8–11, 23].
We performed gene expression profiling on 156 
samples from 41 patients to check for differences in 
expression of PRL-3. The data showed that PRL-3 was 
differentially expressed in normal tissue compared to 
malignant tissue, but there was no significant difference 
between the low-, intermediate- or high-grade samples 
in these data. This is in contrast to other studies find-
ing a positive correlation between PRL-3 expression and 
Fig. 1 Overexpression of PRL-3 in prostate cancer tissue samples compared to normal tissue from the same samples. A total of 156 samples from 
radical prostatectomies were divided in groups based on Gleason score (GS), N (normal tissue, 40 samples), low risk (GS ≤ 6, 38 samples), medium 
risk (GS = 7, 42 samples) and high risk (GS ≥ 8, 36 samples). The groups were analyzed with Illumina gene expression microarray. The panels 
represent four different PRL-3 probes. For all Gleason groups there was a significant difference in gene expression compared with the normal group. 
Asterisks indicates P ≤ 0.05, Two asterisks indicates P ≤ 0.01 and four asterisks indicates P ≤ 0.0001
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degree of malignancy [2–8, 10–12]. Since all our samples 
were from patients with cancer, even the samples consid-
ered as having a normal histology could in fact contain 
molecular changes associated with cancer. In the sam-
ples evaluated with immunohistochemistry, PRL-3 was 
expressed in tissue from primary prostate cancer tumors, 
which is in accordance with Wang et  al. [24], who per-
formed a screening of different human cancers for pro-
tein expression of PRL-3 using immunohistochemistry, 
and found PRL-3 protein in 5/53 (9.4 %) prostate cancer 
samples. We also found the corresponding lymph node 
metastases to express PRL-3 protein. In our immuno-
histochemistry analysis there was no apparent difference 
of PRL-3 protein expression when comparing metastatic 
tissue with primary tumor tissue. This could indicate 
that the change in PRL-3 expression happens early (i.e. 
before metastatic spread) in the molecular development 
of prostate cancer. This does not correspond with studies 
on other carcinomas, where PRL-3 was found to be more 
specifically related to the metastatic spread from the pri-
mary tumor [7, 9, 25], although some articles proposes 
that PRL-3 is involved the early development of cancer 
[26, 27].
By inhibiting PRL-3, we induced growth arrest in the 
cell lines DU145 and PC3. Only at 40  µM did we see a 
significant effect on cell survival assessed with annexin 
V-FITC and PI. This in accordance with both data 
(unpublished) from our lab on normal bone marrow stro-
mal cells and other studies using the same inhibitor on 
other cell types [28]. There are many studies investigating 
Fig. 2 Expression of PRL-3 in prostate cancer cell lines PC3 and DU145, which have an increased copy number of PRL-3 gene locus. a Prostate can-
cer cell lines PC3 and DU145 were analyzed for PRL-3 expression by quantitative RT-PCR. PRL-3 transcript levels were normalized to GAPDH expres-
sion in each sample and presented as relative to the PRL-3 expression in the PC3 cell line, which was set to one. Mean CT values are presented in the 
bars. b PRL-3 protein expression was determined by Western blotting. The INA-6 cell line was used as positive control. GAPDH was used as loading 
control. c, d Fluorescence in situ hybridization with whole chromosome and PRL-3 probe on prostate cancer cell lines PC3 (c) and DU145 (d). The 
red signal marks PRL-3 (8q24.3) and the green signal marks the whole chromosome 8
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the effects of PRL-3 on proliferation. Most of them find 
that PRL-3 promotes proliferation [29–32], although 
results published by Basak et al. [33] indicates that both 
increased and reduced PRL-3 levels can inhibit prolifera-
tion. This suggests that there is a dose–response relation-
ship between the level of PRL-3 and cellular effects, and 
that the effects of PRL-3 may be cell-type dependent. In 
our in vitro cell scratch assay, we assessed the importance 
of PRL-3 in migration, and found a clear reduction when 
inhibiting PRL-3 in the cell line PC3. This is consisted 
with other studies, in which the same inhibitor was used 
[28, 34]. The reduction in migration gives a functional 
explanation and supports the concept that PRL-3 may 
play a role in the development of metastatic disease.
Fig. 3 PRL-3 inhibitor I induced growth arrest and inhibited cell survival at high concentrations in prostate cancer cells. PC3 (a + c) and DU145 
(b + d) cells were seeded in quintuplets in a 96-well plate, incubated in media containing 10 % FCS and with PRL-3-inhibitor I or corresponding 
DMSO concentrations as indicated for 72 h. Cell growth was measured with CellTiter-Glo Luminescent Cell Viability Assay (a + b) or [3H]-thymidine 
incorporation (c + d). Relative luciferase units (RLU) reflect the amount of ATP detected in each well. Figure showing one representative out of four 
experiments. Error bars represent ± one SD of quintuple measurements. Cells were incubated with media containing 10 % FCS and with various 
PRL-3-inhibitor I or highest DMSO concentrations for 72 h. Survival of human prostate cancer cell lines PC3 (e) and DU145 (f) was determined by 
annexin V-FITC/propidium iodide flow cytometry. Figure showing one representative of three experiments. Error bars represent ± one SD of dupli-
cate measurements
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Increased copy number of a gene can increase the 
expressed level of the particular protein that the gene 
encodes. According to our FISH analysis both PC3 and 
DU145 had increased copy number of PRL-3, although 
there was no clear connection between level of PRL-
3 expression and copy-number variations. This result 
is similar to a study on multiple myeloma [35], which 
did not find any consistent relation between number of 
gene copies and level of PRL-3 mRNA. However, since 
our study is limited by the use of only two cell lines, 
this does not rule out that genetic copy number altera-
tions could be important for the expression of PRL-3 in 
prostate cancer. Shin et al. [36] used the prostate cancer 
cell line PC3 to investigate the potential antimetastatic 
effect of a trisoxazole macrolide named halichondra-
mide. Administration of halichondramide led to a con-
centration-dependent inhibition of both migration and 
invasion of the cells, and the suggested mechanism was 
suppression of PRL-3. The gene for PRL-3, PTP4A3, was 
identified as a possible factor involved in tumor progres-
sion in prostate cancer by comparing mRNA-expression 
and copy number alterations [18]. This article reports 
significantly elevated expression in cancer samples com-
pared to benign prostate hyperplasia (BPH), but no dif-
ference between non-aggressive (Gleason score < 8) and 
aggressive (Gleason score ≥ 8) tumor samples. The three 
groups were also compared based on copy number (CN) 
alterations of PRL-3, and there was a significant differ-
ence between aggressive (8/17 had CN gain) and non-
aggressive (1/14 had CN gain) samples. In addition, none 
of the 16 BPH samples analyzed had CN gain. When 
combining their own data with online databases (such 
as Oncomine), PRL-3 was found to be one of two pos-
sible markers for aggressive prostate cancer. In colorectal 
cancer, gene amplification accounts for some overexpres-
sion [37], but in most cases an increased transcriptional 
activity could explain the increased expression. Ooki 
et al. [38] looked at samples from primary gastric tumors, 
and found genomic amplification to be present in 20  % 
of PRL-3-positive tumor samples, and that this ampli-
fication negatively affected the outcome of the patients. 
Several studies have shown that PRL-3 expression is 
influenced by soluble factors in the tumor microenviron-
ment [35, 39, 40]. The full mechanism of how PRL-3 is 
regulated is still not known. The importance and con-
tributing factor of the various mechanisms seems to vary 
with cancer type.
There is little published on the function of PRL-3 in 
normal tissue. PRL-3 protein is detected in tissue from 
fetal rat hearts, but not in adult rat heart, and not in adult 
Fig. 4 PRL-3-inhibitor I blocked the migration of the human prostate cancer cell line PC3. 10 × 105 PC3 cells were seeded in each well in 6-well 
trays with 10 % FCS in RPMI for 48 h to grow a confluent layer. A scratch was made at 0 h through the confluent layer with the tip of a pipette, and 
then the cells were washed carefully with PBS to remove non-adherent cells. Serum free media with indicated concentrations of PRL-3 inhibitor I or 
DMSO (control) were added, and the cells incubated for 16 h
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human heart [24]. Guo et al. [24] also found that PRL-3 
protein is non-detectable in mature red blood cells and 
mature blood vessels. Despite the lack of literature on 
PRL-3 in mature tissues, heart or skeletal muscle have 
been described as positive controls for PRL-3 immuno-
histochemistry among antibody producers, indicating 
PRL-3 protein expression in these tissues. The possible 
lack of PRL-3 in normal tissue makes a PRL-3 inhibitor 
an attractive agent in cancer treatment. Our microarray 
data confirm that PRL-3 is differentially expressed in can-
cer tissue versus normal tissue. This supports a role for 
PRL-3 in prostate carcinogenesis, but not specifically to 
metastasis. This might reflect that PRL-3 acts differently 
in prostate cancer than in other carcinomas, where it 
often is more specific for metastatic lesions. A quite small 
group of cancer patients and no healthy control limits 
our study. Nonetheless, the increased proliferation and 
migration due to PRL-3, and the increased expression of 
PRL-3 mRNA in malignant samples from cancer patients, 
indicates that PRL-3 inhibition could be a reasonable 
strategy in prostate cancer treatment.
Conclusions
This is the first study to investigate the functional role of 
PRL-3 in prostate cancer. We found that PRL-3 is present 
on both mRNA and protein level in human prostate can-
cer samples and corresponding lymph node metastases, 
and that the expression of mRNA is higher in malignant 
samples compared to normal samples. PRL-3 was also 
present on both mRNA and protein levels in the prostate 
cancer cell lines DU145 and PC3, and inhibition of PRL-3 
by a small molecular inhibitor induced growth arrest and 
inhibited migration in the prostate cancer cells in a dose-
dependent manner. These results suggest that PRL-3 
could be a potential therapeutic target in prostate cancer.
Additional file
Additional file 1: Figure S1. Further explanation of method used to 
adjust for stromal contribution to the samples in the gene expression pro-
filing. P values for the four probes used in the tissue microarray analysis. All 
P values are compared to the samples classified as normal.
Fig. 5 Expression of PRL-3 in primary tumors and lymph node metastasis in prostate cancer tissue samples. Immunohistochemistry staining of 
primary prostate cancer tumor (a—Patient 1–4) with corresponding metastases (b—Patient 1–4). 100× magnification H&E = Hematoxylin and 
eosin stain a Patient 1 Gleason pattern 3 and 4, Patient 2 Gleason pattern 4, Patient 3 Gleason pattern 3 and 4, and Patient 4 Gleason pattern 3 and 4. 
Patient 2, 3 and 4 also has histologically normal glands in the sample (arrowheads). IHC show PRL-3 expression in malignant glands, some histologi-
cally normal glands are also positive (green arrowhead), whereas others are negative (black arrowheads). b All corresponding lymph node metastases 
express PRL-3
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